Relative potency of prorenoate potassium and spironolactone in attenuating diuretic induced hypokalaemia.
The plasma potassium responses to the aldosterone antagonists prorenoate K (10 mg/day and 40 mg/day) and spironolactone (25 mg/day and 100 mg/day) were compared following treatment for 11 days in combination with the diuretic metolazone (2.5 mg/day) in a double-blind crossover study in twelve healthy men. The best estimate of the potency of prorenoate K relative to spironolactone in attenuating metolazone induced hypokalaemia was 5.6 with 95% confidence limits 2.4-35.2. The method employed allowed a statistically valid quantitative comparison of the potassium sparing properties of the mineralocorticoid antagonists after repeated doses and may be useful in the preclinical evaluation of these drugs.
D000328:Adult; D002192:Canrenone / Q000097:blood; D004232:Diuretics / Q000037:antagonists & inhibitors*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008788:Metolazone / Q000037:antagonists & inhibitors; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology; D011188:Potassium / Q000097:blood*; D013148:Spironolactone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology*
D004232:Diuretics; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; C016699:prorenone; D002192:Canrenone; D011188:Potassium; C010768:prorenoate potassium; D008788:Metolazone